• 1
    Curran WJ. New chemotherapeutic agents: update of major chemoradiation trials in solid tumors. Oncology. 2002; 63( suppl 2): 29-38.
  • 2
    Spalding AC, Lawrence TS. New and emerging radiosensitizers and radioprotectors. Cancer Invest. 2006; 24: 444-456.
  • 3
    Sharma VM, Wilson WR. Radiosensitization of advanced squamous cell carcinoma of the head and neck with cisplatin during concomitant radiation therapy. Eur Arch Otorhinolaryngol. 1999; 256: 462-465.
  • 4
    Awada A, Ismael G. The challenging integration of platinum compounds, taxanes, and molecular-targeted therapies in the multidisciplinary treatment of squamous cell carcinoma of the head and neck. Curr Opin Oncol. 2007; 19: 177-179.
  • 5
    Hao D, Ritter MA, Oliver T, Browman GP. Platinum-based concurrent chemoradiotherapy for tumors of the head and neck and the esophagus. Semin Radiat Oncol. 2006; 16: 10-19.
  • 6
    Green J, Kirwan J, Tierney J, et al. Concomitant chemotherapy and radiation therapy for cancer of the uterine cervix. Cochrane Database Syst Rev. 2005; (3): CD002225.
  • 7
    Brizel DM, Esclamado R. Concurrent chemoradiotherapy for locally advanced, nonmetastatic, squamous carcinoma of the head and neck: consensus, controversy, and conundrum. J Clin Oncol. 2006; 24: 2612-2617.
  • 8
    Thatcher N, Faivre-Finn C, Blackhall F, Anderson H, Lorigan P. Sequential platinum-based chemotherapy-thoracic radiotherapy in early stage non-small cell lung cancer. Clin Cancer Res. 2005; 11(13 pt 2): 5051s-5056s.
  • 9
    Warnke U, Rappel C, Meier H, et al. Analysis of platinum adducts with DNA nucleotides and nucleosides by capillary electrophoresis coupled to ESI-MS: indications of guanosine 5′-monophosphate O6-N7 chelation. Chembiochem. 2004; 5: 1543-1549.
  • 10
    Scagliotti G. Optimizing chemotherapy for patients with advanced non-small cell lung cancer. J Thorac Oncol. 2007; 2( suppl 2): S86-S91.
  • 11
    Mey UJ, Orlopp KS, Flieger D, et al. Dexamethasone, high-dose cytarabine, and cisplatin in combination with rituximab as salvage treatment for patients with relapsed or refractory aggressive non-Hodgkin's lymphoma. Cancer Invest. 2006; 24: 593-600.
  • 12
    Colevas AD. Chemotherapy options for patients with metastatic or recurrent squamous cell carcinoma of the head and neck. J Clin Oncol. 2006; 24: 2644-2652.
  • 13
    Bernier J, Cooper JS. Chemoradiation after surgery for high-risk head and neck cancer patients: how strong is the evidence? Oncologist. 2005; 10: 215-224.
  • 14
    Coderre JA, Turcotte JC, Riley KJ, Binns PJ, Harling OK, Kiger WS,3rd. Boron neutron capture therapy: cellular targeting of high linear energy transfer radiation. Technol Cancer Res Treat. 2003; 2: 355-375.
  • 15
    Couturier O, Supiot S, Degraef-Mougin M, et al. Cancer radioimmunotherapy with alpha-emitting nuclides. Eur J Nucl Med Mol Imaging. 2005; 32: 601-614.
  • 16
    Forman JD, Yudelev M, Bolton S, Tekyi-Mensah S, Maughan R. Fast neutron irradiation for prostate cancer. Cancer Metastasis Rev. 2002; 21: 131-135.
  • 17
    Boeckman HJ, Trego KS, Turchi JJ. Cisplatin sensitizes cancer cells to ionizing radiation via inhibition of nonhomologous end joining. Mol Cancer Res. 2005; 3: 277-285.
  • 18
    Wilson GD, Bentzen SM, Harari PM. Biologic basis for combining drugs with radiation. Semin Radiat Oncol. 2006; 16: 2-9.
  • 19
    Hall EJ. Radiobiology for the Radiologist, 5th ed. Philadelphia, Pa: Lippincott Williams & Wilkins; 2000.
  • 20
    International Commission for Radiological Protection (ICRP). Age-dependent Doses to Members of the Public from Intake of Radionuclides: Part 2 Ingestion Dose Coefficients. ICRP Publication 67. Oxford, United Kingdom: Pergamon Press; 1993.
  • 21
    Pouget J-P, Mather SJ. General aspects of the cellular response to low- and high-LET radiation. Eur J Nucl Med. 2001; 28: 541-561.
  • 22
    Abend M. Reasons to reconsider the significance of apoptosis for cancer therapy. Int J Radiat Biol. 2003; 79: 927-941.
  • 23
    Cherel M, Davodeau F, Kraeber-Bodere F, Chatal JF. Current status and perspectives in alpha radioimmunotherapy. Q J Nucl Med Mol Imaging. 2006; 50: 322-329.
  • 24
    Nilsson S, Larsen RH, Fossa SD, et al. First clinical experience with alpha-emitting radium-223 in the treatment of skeletal metastases. Clin Cancer Res. 2005; 11: 4451-4459.
  • 25
    Arazi L, Cooks T, Schmidt M, Keisari Y, Kelson I. Treatment of solid tumors by interstitial release of recoiling short-lived alpha emitters. Phys Med Biol. 2007; 52: 5025-5042.
  • 26
    Cooks T, Arazi L, Schmidt M, Marshak G, Kelson I, Keisari Y. Growth retardation and destruction of experimental squamous cell carcinoma by interstitial radioactive wires releasing diffusing alpha-emitting atoms. Int J Cancer. 2008; 122: 1657-1664.
  • 27
    Murdoch D. Standard, and novel cytotoxic and molecular-targeted, therapies for HNSCC: an evidence-based review. Curr Opin Oncol. 2007; 19: 216-221.
  • 28
    Blank M, Lavie G, Mandel M, et al. Antimetastatic activity of the photodynamic agent hypericin in the dark. Int J Cancer. 2004; 111: 596-603.
  • 29
    Ziegler JF. Stopping and ranges in matter (SRIM). Available at Accessed on January 25, 2009.
  • 30
    Carlsson J, Eriksson V, Stenerlow B, Lundqvist H. Requirements regarding dose rate and exposure time for killing of tumour cells in beta particle radionuclide therapy. Eur J Nucl Med Mol Imaging. 2006; 33: 1185-1195.
  • 31
    Fields MT, Eisbruch A, Normolle D, et al. Radiosensitization produced in vivo by once- versus twice-weekly 2′2′-difluoro-2′-deoxycytidine (gemcitabine). Int J Radiat Oncol Biol Phys. 2000; 47: 785-791.
  • 32
    Rosenthal DI, Lee JH, Sinard R, et al. Phase I study of paclitaxel given by 7-week continuous infusion concurrent with radiation therapy for locally advanced squamous cell carcinoma of the head and neck. J Clin Oncol. 2001; 19: 1363-1373.
  • 33
    Varveris H, Mazonakis M, Vlachaki M, et al. A phase I trial of weekly docetaxel and cisplatinum combined to concurrent hyperfractionated radiotherapy for non-small cell lung cancer and squamous cell carcinoma of head and neck. Oncol Rep. 2003; 10: 185-195.
  • 34
    Calais G, Alfonsi M, Bardet E, et al. Randomized trial of radiation therapy versus concomitant chemotherapy and radiation therapy for advanced-stage oropharynx carcinoma. J Natl Cancer Inst. 1999; 91: 2081-2086.
  • 35
    Jeremic B, Shibamoto Y, Milicic B, et al. Hyperfractionated radiation therapy with or without concurrent low-dose daily cisplatin in locally advanced squamous cell carcinoma of the head and neck: a prospective randomized trial. J Clin Oncol. 2000; 18: 1458-1464.
  • 36
    Pignon JP, Bourhis J, Domenge C, Designe L. Chemotherapy added to locoregional treatment for head and neck squamous-cell carcinoma: 3 meta-analyses of updated individual data. MACH-NC Collaborative Group Metaanalysis of chemotherapy on head and neck cancer. Lancet. 2000; 355: 949-955.
  • 37
    Adelstein DJ, Li Y, Adams GL, et al. An intergroup phase III comparison of standard radiation therapy and 2 schedules of concurrent chemoradiotherapy in patients with unresectable squamous cell head and neck cancer. J Clin Oncol. 2003; 21: 92-98.